0.540
+0.090
(20.00%)
May 22 - Close
OTCBB
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.45 - 0.54 |
| 52 week | 0.30 - 1.30 |
| Open | 0.45 |
| Vol / Avg. | 23,825.00/6,201.00 |
| Mkt cap | 24.31M |
| P/E | - |
| Div/yield | - |
| EPS | -0.10 |
| Shares | 45.03M |
| Beta | -18.17 |
| Inst. own | - |
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -390.00% | -382.80% |
| Return on average equity | -1285.45% | -975.04% |
| Employees | 4 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 1225, 888 Dunsmuir Street
VANCOUVER, BC V6C 3K4
Canada
+1-604-2488730 (Phone)
+1-604-2488690 (Fax)
VANCOUVER, BC V6C 3K4
Canada
+1-604-2488730 (Phone)
+1-604-2488690 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
RepliCel Life Sciences Inc. (RepliCel), formerly Newcastle Resources Ltd. is a Canada-based company, engaged in the business of developing and patenting hair follicle cell replication technology. The Company�s cellular replication and implantation technology is designed to rejuvenate damaged, miniaturized hair follicles in balding scalp skin. The Company is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women. It is focused on ensuring the safety and demonstrating the efficacy of RepliCel�s cell-based hair regeneration procedure in humans. As of September 30, 2012, the Company�s subsidiary included TrichoScience Innovations Inc. (TrichoScience).